Action in Diabetes Read more about the ADVANCE trial on The George Institute website A factorial, randomised controlled trial study designed to determine the effects of intensive blood pressure lowering and glucose control on cardiovascular risks among type 2 diabetes patients. Covering both advanced economies in North America and Western Europe and emerging economies in […]
了解更多As active contributors in research, sometimes it’s nice to take a step back and reflect how our work evolves from novel treatment to everyday practice.
了解更多Evidence is increasing of the benefits, without increased risks, of using dual antiplatelet therapy – aspirin and clopidogrel – as soon as possible and continued for up to 3-months in patients with minor acute ischaemic stroke or transient ischaemic stroke (TIA), so-called mini-strokes. The evidence is derived from multiple randomised controlled trials, including a recent […]
了解更多The recent SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials recently reported the effects of the DPPIV inhibitor class of glucose lowering agents in people with diabetes. As required by the US FDA, both drugs were found not to increase cardiovascular risk, allowing the agents to be registered for use in that country. Good news, it would […]
了解更多
Intracerebral hemorrhage is the most serious form of stroke with high rates of mortality and a low chance of recovery to functional independence. In Asia-Pacific, it affects more than one million people annually, kills one third of them and leaves most survivors with disability. For reasons yet unknown, intracerebral hemorrhage is also more prevalent in […]
了解更多
COPD is one of the world’s leading cause of death with prevalence ranging from 6% to 19% globally. This disease is particularly relevant for us in Asia-Pacific as risk factors such as smoking, biomass fuels, TB and air pollution are more prevalent than other regions. For example COPD prevalence in Chinese males is estimated to […]
了解更多
Diseases that dominate the 21st century need a 21st century approach in the way we design and conduct clinical trials. To meet this need, 乔治临床( George Clinical ) is primarily focused on large-scale studies with high-impact outcomes, particularly where smaller pre-registration trials need to be expanded to larger populations. 乔治临床( George Clinical ) has been […]
了解更多
Cancer is well established as a major leading cause of death across the world. Perhaps what is less known is that 70% of these deaths occur in low and middle-income countries, with Asia absorbing most of the impact. In 2002, 3.5 million people died of cancer in Asia. This is expected to increase to 8.1 […]
了解更多One quarter of the world’s adult population suffers from hypertension, and although it has no obvious symptoms, it can lead to heart attacks, stroke, kidney failure and blindness. Despite this, there has been great uncertainty as to how intensively blood pressure should be lowered to obtain maximal benefit and minimize risks. Researchers from Australia, China, […]
了解更多
